



**BANVİT BANDIRMA VİTAMİNLİ YEM SANAYİ ANONİM ŞİRKETİ**  
**01 JAN 2026 – 31 MARCH 2026 INTERIM PERIOD ACTIVITY REPORT**

**TABLE OF CONTENTS****A. General Information**

1. Reporting Period
2. Information Regarding the Company
3. Shareholding Structure and Capital Distribution
4. Explanations on Privileged Shares and Voting Rights
5. Information on the Members of the Board of Directors and Senior Executives
6. Employee and Worker Movements, Collective Bargaining Practices, and Rights and Benefits Provided to Employees and Workers
7. Corporate Governance Principles Compliance Report
8. Amendments Made to the Articles of Association

**B. Financial Rights Provided to Members of the Board of Directors and Executives**

1. Total Amount of Financial Benefits Such as Attendance Fees, Salaries, Bonuses, Premiums, and Profit Shares
2. Information on Allowances, Travel, Accommodation and Representation Expenses, In-kind and Cash Benefits, Insurance, and Similar Guarantees

**C. Research and Development Activities****D. Company Activities and Significant Developments Related to Activities**

1. Investment Activities
2. Internal Control System and Internal Audit Activities
3. Direct and Indirect Subsidiaries

**E. Financial Position**

1. Summary of Financial Statements
2. Key Financial Ratios
3. Development of Financing Resources and Policies Implemented by the Company Within This Framework
4. Nature and Amount of Capital Market Instruments Issued
5. General Assembly
6. Dividend Distribution
7. The Sector in Which the Company Operates and Its Position Within the Sector
8. Incentives
9. Development of the Company
10. Developments in Sales

**F. Risk Management**

1. Corporate Risk Management
2. Early Detection of Risk Committee



## **G. Other Matters**

1. Organizational Structure
2. Sustainability Principles
3. Significant Developments
4. Significant Developments Occurring After the Reporting Period

## **H. Investor Relations**



## A. General Information

### 1) Reporting Period

01.01.2026 – 31.03.2026

### 2) Information Regarding the Company

<b>Trade Name:</b>	Banvit Bandırma Vitaminli Yem Sanayi A.Ş.
<b>Trade Registry Number:</b>	4153
<b>Tax Office:</b>	Bandırma
<b>Tax Identification Number:</b>	1400036590
<b>Registered Office Address:</b>	Ömerli Mah. Ömerli Sok. No: 2/8 A Bandırma- Balıkesir
<b>Telephone and Fax:</b>	Tel: (0266) 733 86 00 Pbx   Faks: (0850) 2001052
<b>Website:</b>	www.banvitas.com
<b>Registered Capital Ceiling:</b>	8,000,000,000 TRY
<b>Paid-in/Issued Capital:</b>	100,023,579 TRY

### 3) Shareholding Structure and Capital Distribution

Shareholders	Number of Shares	%
BRF GMBH	55,036,207.82	55.02
QATAR HOLDING LLC	36,690,804	36.68
Published Traded	8,296,567.18	8.30
Total	100,023,579	100.00

There has been no change in the direct shareholding structure and capital distribution during the period.

### 4) Explanations on Privileged Shares and Voting Rights

There are no privileged shares in the Company's capital, and each shareholder is entitled to one (1) voting right per share.

### 5) Information on the Members of the Board of Directors and Senior Executives

In accordance with the provisions of the Turkish Commercial Code ("TCC") and the relevant regulations, as well as the Company's Articles of Association, the election of the members of the Board of Directors is carried out by the General Assembly. In cases where changes occur in the composition of the Board of Directors during the period, elections are conducted in line with the provisions of the TCC and the Company's Articles of Association, and such changes are submitted to the approval of the General Assembly. Any changes made during the period are effected by a resolution of the Board of Directors and are presented for approval at the next Ordinary General Assembly meeting.

Pursuant to the provisions of the TCC and the Capital Markets Law, at the Ordinary General Assembly Meeting held on May 9, 2023, which was registered by the Bandırma Trade Registry Office on May 17, 2023, and in accordance with Article 8 of the Company's Articles of Association, eight (8) members of the Board of Directors, including three (3) independent members, were elected by the General Assembly to serve for a term of three (3) years.



Members of the Board of Directors in Office as of March 31, 2026:

Name	Position	Term of Office
Fabio Luis Mendes Mariano	Chairman of the Board	09.05.2023 – 09.05.2026
Heraldo Geres	Deputy Chairman of the Board	10.10.2025 – 09.05.2026
Tang David	Member of the Board	10.10.2025 – 09.05.2026
Davide Luigi Vimercati	Member of the Board	09.05.2023 – 09.05.2026
Feras Abdulaziz M H Al-Naama	Member of the Board	09.05.2023 – 09.05.2026
Meral Kurdaş	Member of the Board	09.05.2023 – 09.05.2026
Selim Taşo	Member of the Board	09.05.2023 – 09.05.2026
Ali Ferda Elerman	Member of the Board	09.05.2023 – 09.05.2026

#### ***Duties and Authorities of the Members of the Board of Directors***

The Board of Directors performs and executes the duties assigned to it by the decisions of the General Assembly in accordance with the provisions of the Turkish Commercial Code (TCC), the Capital Markets Law, other applicable regulations, and Article 9 of the Company's Articles of Association.

Executive Management – As of March 31, 2026:

Name	Position	Date of Appointment
Tolga Gündüz	General Manager	16.10.2019
Levent Aytimur	Finance Director	09.01.2023
Nerdin Alp	Sales Director	06.04.2001
Atakan Sakin	Logistics Director	01.06.2022
Gökçen Aslan Özşar	Human Resources Director	27.09.2021
Miray Baran	Legal and Corporate Affairs Director	23.09.2021
Erdal Elmas	Operations Director	01.02.2095
Özlem Kutluk	Business Planning and Development Director	12.01.2003
Paul George Caneja Sarmiento	Quality Assurance and R&D Director	01.05.2025
Gökçe Uysal Kurer	Marketing and Corporate Communications Director	05.05.2025

#### **6) Personnel and Worker Movements, Collective Bargaining Practices, and Rights and Benefits Provided to Employees and Workers**

In the food industry line of business, the wages and fringe benefits of our blue-collar employees are subject to a collective bargaining agreement. Our white-collar employees are not covered by any collective agreement.

In addition to base salaries, our employees are provided with bonuses, marriage assistance, health insurance, profit-sharing payments from the Company's annual earnings, product assistance, meal allowance, and transportation allowance. Leave entitlements include annual paid leave, excuse leave, unpaid leave, as well as marriage leave, bereavement leave, pregnancy-related leave, maternity leave, and nursing leave.



Number of Employees of Banvit Bandırma Vitaminli Yem Sanayi A.Ş. as of March 31, 2026 and December 31, 2025:

	31.03.2026	31.12.2025
Blue Collar	3695	4095
White Collar	640	668
Total	4335	4763

## 7) Corporate Governance Principles Compliance Report

In accordance with the Capital Markets Board (CMB) resolution dated January 10, 2019 and numbered 2/49, the Company's Corporate Governance Compliance Report (URF), which presents the Company's compliance status with the mandatory and voluntary Corporate Governance Principles, and the Corporate Governance Information Form (KYBF), which provides information on the Company's current corporate governance practices, have been published on the Public Disclosure Platform (KAP) using the relevant templates and are publicly available at the following addresses:

<https://www.kap.org.tr/tr/Bildirim/1396391> and <https://www.kap.org.tr/tr/Bildirim/1396389>.

Information regarding corporate governance can also be accessed through the following link: <https://www.kap.org.tr/tr/cgif/4028e4a1415f4d990141601902e33250>

In line with the CMB Communiqué on Corporate Governance (II-17.1) and the CMB Resolution No. 2/49 dated January 10, 2019, an integrated internal audit, internal control, and compliance management system has been established within the Company to ensure the sustainability of compliance with corporate governance principles.

The Internal Audit Department evaluates the Company's operations in terms of compliance with legislation, internal regulations, and ethical standards in line with the risk-based audit plan. Auditors operate in accordance with the principles of independence and objectivity. Findings and recommended actions are reported to the Audit Committee and the Board of Directors.

The Internal Control Department, which conducts its activities based on COSO standards, ensures segregation of duties on a process basis and assesses the effectiveness and efficiency of the Company's systems and processes through continuous monitoring and control testing. In order to eliminate existing or potential risk factors, the department coordinates with process owners to determine, implement, and sustain applicable action plans. These activities aim to ensure the effective functioning of the control environment within the Company.

The Compliance Department monitors adherence to legal regulations as well as to the Company's internal policies and procedures. Compliance risks are identified and monitored; regular training sessions are provided to employees, and secure and anonymous ethics channels are made available for reporting any potential misconduct or violations. All activities are regularly reported to senior management.

The Audit Committee evaluates the effectiveness of internal systems, monitors independent audit processes, and ensures the compliance of financial reporting with applicable regulations. The Committee convenes at least four times a year and reports its findings and recommendations to the Board of Directors.

This structure supports the sustainability of compliance with corporate governance principles, as well as transparency and accountability at the corporate level.

## 8) Amendments Made to the Articles of Association

No amendments were made to the Articles of Association during the reporting period.

### B. Financial Rights Provided to Members of the Board of Directors and Senior Executives

#### 1. Total Amount of Financial Benefits Such as Attendance Fees, Salaries, Bonuses, Premiums, and Profit Shares Provided

At the Ordinary General Assembly Meeting of the Company held on May 22, 2025, it was resolved not to pay any remuneration to the members of the Board of Directors, and to pay each Independent Member of the Board of Directors a gross monthly fee/attendance fee of TRY 116.250,00, starting from the month following the General Assembly and continuing until the next Ordinary General Assembly.

The salaries of senior executives are determined by the Company's Board of Directors. All senior executives are covered by private health insurance.

For the accounting period ended March 31, 2026, all benefits provided to senior executives are short-term benefits and include salaries, bonuses, and other payments.

Within the Company, including senior executives, non-union personnel receive performance-based additional payments.

Between January 1, 2026 and March 31, 2026, total payments made to senior executives amounted to TRY 21,235,711.86 , with TRY 1,192,932.60 withheld as employer's social security contributions. In addition, during the same period (01.01.2026 – 31.03.2026), a total of TRY 1,046,250.00 was paid to three independent members of the Board of Directors as attendance fees.

During the period, no loans were extended to any members of the Board of Directors or executives, no credit was made available to them directly or through third parties under the name of personal loans, and no guarantees such as sureties were provided in their favor.

Between January 1, 2026 and March 31, 2026, the total amount of benefits provided to the members of the Board of Directors and senior executives was TRY 24,194,894.46 (March 31, 2025: TRY 18,607,697). No performance-based payments were made to the members of the Board of Directors.

During the period, no loans were extended to any Board members or executives, no personal loans were granted directly or through third parties, and no guarantees or sureties were provided on their behalf.

#### 2. Information on the Total Amount of Allowances, Travel, Accommodation and Representation Expenses, In-kind and Cash Benefits, Insurances, and Similar Guarantees Provided

The total amount of allowances, travel, accommodation and representation expenses, in-kind and cash benefits, and insurances provided to the members of the Board of Directors and senior executives during the period was TRY 3,262,157.47.



### **C. Research and Development Activities**

In order to meet the demands and needs of our consumers, customers, and supplier companies in a creative, high-quality, practical, and delicious manner, our Company carries out research and development (R&D) activities focused on product development and the production of new products. In addition, our R&D efforts also cover areas such as identifying and implementing the most suitable and recyclable packaging for our products and ensuring effective waste management, thereby contributing to the Company's overall sustainability initiatives.

Within this scope, during the period from January 1, 2026 to March 31, 2026, 4 new products and 4 new packaging types were developed. The Company also aims to increase the share of recyclable materials used in its packaging diversity. As a result of new product additions and discontinued items during the same period, the usage rate of recyclable packaging materials reached 92%.

### **D. Company Activities and Significant Developments Related to Activities**

#### **1) Investment Activities**

As of March 31, 2026, the total investment expenditures of Banvit Bandırma Vitaminli Yem Sanayi A.Ş. amounted to TRY 95,309,778 (March 31, 2025: TRY 20,917,420).

#### **2) Internal Control System and Internal Audit Activities**

The Internal Audit Department provides the Board of Directors with independent and objective reasonable assurance regarding the Company's corporate governance processes. The Internal Audit activities aim to offer reasonable assurance to the Company's stakeholders, primarily its shareholders, concerning managerial accountability, the efficiency and effectiveness of business processes, the reliability of the financial reporting system, and the compliance of Company activities with laws and regulations. The Internal Audit activities are carried out in accordance with the "International Standards for the Professional Practice of Internal Auditing" established by the Institute of Internal Auditors (IIA). The Internal Audit Department operates in compliance with the "Banvit Internal Audit Charter" and monitors audit findings until the associated risks are fully mitigated.

The Internal Control Department carries out activities related to the early identification, assessment, and evaluation of risks that may affect the Company; the calculation of their impact and likelihood; and the management of these risks in line with the Company's corporate risk appetite. The department also ensures the reporting of risks, the implementation of necessary measures to reduce their impact and likelihood, and the establishment of effective internal control systems in this context. The Internal Control Department aims to ensure reliable financial reporting and effective risk management in accordance with the core components of internal control, which consist of control environment, risk assessment, control activities, information and communication, and monitoring.

#### **3) Direct and Indirect Subsidiaries**

As of March 31, 2026, Banvit Bandırma Vitaminli Yem Sanayi A.Ş. has no direct or indirect subsidiaries.

## E. Financial Position

### 1) Summary of Financial Statements

The financial statements have been prepared in accordance with the financial reporting standards issued by the Capital Markets Board (CMB). In line with the Board of Directors' resolution No. 2021/22 dated October 6, 2021, the Company's first and third quarter interim financial statements are not subject to independent audit. A related material event disclosure was published on the Public Disclosure Platform (KAP) on October 7, 2021.

#### Summary Statement of Financial Position (Balance Sheet Summary)

	Not Reviewed	Audited
(TRY)	January 1 – March 31, 2026	January 1 – December 31, 2025
<b>Current Assets</b>	15,584,504,770	18,131,399,567
<b>Non-Current Assets</b>	9,446,557,428	9,582,431,194
<b>Total Assets</b>	<b>25,031,062,198</b>	<b>27,713,830,761</b>
<b>Current Liabilities</b>	12,106,801,091	13,808,574,947
<b>Non-Current Liabilities</b>	1,538,152,374	1,722,483,909
<b>Equity</b>	11,386,108,733	12,182,771,905
<b>Total Liabilities and Equity</b>	<b>25,031,062,198</b>	<b>27,713,830,761</b>

#### Summary Statement of Profit or Loss (Income Statement Summary)

	Not Reviewed	Not Reviewed
(TRY)	January 1 – March 31, 2026	January 1 – March 31, 2025
<b>Sales</b>	7,890,170,046	10,039,441,359
<b>Gross Profit</b>	(216,640,525)	1,181,725,297
<b>EBITDA</b>	(558,914,662)	769,025,162
<b>Net Profit/(Loss)</b>	(796,663,172)	(18,528,356)

The Company prepares its annual budget in accordance with its strategic objectives, and the budget is approved by the Board of Directors. During regular Board meetings, the Company's current position is reviewed, and its performance is compared with both the previous period and the approved budget targets.

### 2) Key Financial Ratios

(%)	January 1 – March 31, 2026	January 1 – March 31, 2025
<b>Gross Profit Margin</b>	(2.75%)	11.77%
<b>EBITDA Margin</b>	(7.08%)	7.7%
<b>Net Profit/(Loss) Margin</b>	(10.10)	(0.18)
<b>Earnings/(Loss) per Share</b>	(7.96)	(0.18)



### 3) Development of Financing Resources and the Policies Implemented by the Company Within This Framework

The Company continuously researches new financing alternatives suited to market conditions and evaluates the proposed options. Its borrowing policy is developed based on a strong equity structure and high cash generation capacity. Hedging methods and ratios to mitigate potential financial risks are determined within a defined model framework.

### 4) Nature and Amount of Capital Market Instruments Issued

No capital market instruments were issued during the period.

### 5) General Assembly

Pursuant to the resolution of our Board of Directors dated 30 March 2026, it has been decided that the Ordinary General Assembly Meeting for the year 2025 will be held on Friday, 8 May 2026 at 11:00 a.m. at the Banvit facilities located at Ömerli Mahallesi, Ömerli Sokak No: 2/8A, Bandırma/Balıkesir, Türkiye. Our announcement regarding the Ordinary General Assembly Meeting was published on the Public Disclosure Platform (KAP) on 30 March 2026. The Ordinary General Assembly Meeting of our Company relating to the accounting period from 1 January 2025 to 31 December 2025 will be held on 8 May 2026 at our Bandırma address.

<https://kap.org.tr/tr/Bildirim/1578989>

### Agenda of Banvit Bandırma Vitaminli Yem Sanayi A.Ş. 2025 Ordinary General Assembly Meeting

1. Opening of the meeting and establishment of the Meeting Presidency.
2. Reading and discussion of the Board of Directors' Annual Activity Report regarding the 2025 accounting period.
3. Reading of the summary of the Independent Auditor's Report regarding the 2025 accounting period.
4. Reading, discussion, and approval of the Financial Statements regarding the 2025 accounting period.
5. Separate discharge of the members of the Board of Directors for the Company's activities during the 2025 accounting period.
6. Determination of the number and terms of office of the members of the Board of Directors and election of the members of the Board of Directors and Independent Board Members within the framework of the determined principles.
7. Discussion and resolution of the Board of Directors' proposal, prepared within the framework of the Company's dividend distribution policy, regarding the appropriation of the 2025 profit and profit distribution.
8. Informing shareholders about (i) the "Remuneration Policy for Board Members and Senior Executives" and (ii) the benefits provided to board members and senior executives during the year 2025.
9. Determination of the annual and/or monthly remuneration of the members of the Board of Directors.
10. Submission for the approval of the General Assembly of the members of the Board of Directors elected due to vacancies arising on the Board of Directors pursuant to Article 363 of the Turkish Commercial Code.
11. Discussion and resolution of the proposal of the Board of Directors regarding the selection of the independent external audit firm.
12. Informing shareholders about the donations made by the Company during the 2025 financial year and discussion and resolution of the upper limit for donations to be made during the 2026 financial year.
13. Informing shareholders about the guarantees, pledges, mortgages, and sureties provided by the Company in favor of third parties during 2025, as well as the income or benefits obtained therefrom.
14. Informing shareholders about transactions carried out with related parties during the year 2025.

15. Informing shareholders about transactions carried out during 2025 by controlling shareholders, members of the Board of Directors, executives with administrative responsibility, and their spouses and relatives by blood or marriage up to the second degree.
16. Granting permission to the members of the Board of Directors pursuant to Articles 395/1 and 396 of the Turkish Commercial Code.
17. Wishes and opinions.
18. Closing.

## 6) Dividend Distribution

Article 23 of the Company's Articles of Association, titled "Determination and Distribution of Profit," sets out the following principles regarding the determination and distribution of profit:

The method and timing of profit distribution shall be determined by the General Assembly based on the proposal of the Board of Directors. However, the distribution period of the year-end dividends shall not exceed the period specified in the communiqués of the Capital Markets Board.

Dividends shall be distributed equally to all existing shares as of the distribution date, regardless of their issuance and acquisition dates. No dividend distribution was made during the period.

According to the Company's financial statements for the accounting period from 1 January 2025 to 31 December 2025, which were prepared in accordance with the Capital Markets Board's Communiqué on Principles of Financial Reporting in Capital Markets (II-14.1) and independently audited by Eren Bağımsız Denetim A.Ş., the Company recorded a loss in the amount of TRY 3,115,210,956 (TRY 254,242,280 according to the records prepared in accordance with the Tax Procedure Law). As there is no distributable profit for the relevant period, no dividend distribution will be made. Accordingly, it has been resolved that the said loss be added to prior years' losses and that this matter be submitted for the approval of the shareholders at the Company's first General Assembly Meeting. <https://kap.org.tr/Bildirim/1579005>

## 7) The Sector in Which the Company Operates and Its Position Within the Sector

As Banvit, we began our operations in 1968 as a small-scale feed producer. In 1984, we entered the poultry meat production business. At that time, we became the first company in Türkiye to offer cleaned, fresh poultry meat to consumers in packaged and branded form, thereby assuming a pioneering role in our industry. In 2001, we commissioned our Further Processing Facilities, expanding our production portfolio. Through these investments, we began offering consumers convenient, ready-to-cook and ready-to-eat products such as nuggets, döner, kebabs, meatballs, and delicatessen products. In addition to our main production facilities in Bandırma, we expanded our operations by opening additional production facilities in İzmir and, in subsequent years, in Elazığ, enabling us to serve millions of consumers both domestically and internationally.

Last year, we proudly celebrated the 57th anniversary of our presence in the sector. Today, Banvit is pleased to be among Türkiye's leading food companies, providing daily service to its customers with a broad product portfolio. In addition to the Banvit master brand, we continue to serve different customer segments and needs through our sub-brands.

While implementing new initiatives with the vision of strengthening our pioneering position in the sector, we act in line with our mission to creatively, qualitatively, and deliciously meet consumer and customer expectations; to contribute to providing reliable animal protein produced under hygienic conditions that meet nutritional needs; and to remain sensitive to environmental sustainability, animal welfare, and employee well-being.

## 8) Incentives

The Company holds several rights and incentives that are available to all entities meeting the legal criteria, regardless of their sector of activity. These include:

- Investment Incentive Certificates
- Inward Processing Authorization Certificates (Exemption from Customs Duty, VAT exemption, corporate tax incentives, and employer's share of social security premium support)
- Social Security Institution (SSI) Incentives
- Energy Support

## 9) The Development of the Company

The Company's production of finished poultry meat for the first three months of 2026 decreased by 10.2% compared to the same period of the previous year. Production of further processed products also recorded a year-on-year decrease of 1.8%.

Approximately 9.4% of the total poultry and further processed products produced were exported. In 2026, domestic sales declined by 15.4% compared to the previous year, while export volumes increased by 26.5%.

Overall poultry production data for Türkiye is updated based on statistics published by the Turkish Statistical Institute (TURKSTAT). The data is released on a monthly basis, with a two-month reporting lag.

According to TURKSTAT data, during the January–February 2026 period, the quantity of chicken meat supplied to the domestic market increased by 1.0% compared to the same period of the previous year, while exported volumes increased by 18.2%.

Total production during the January–February period of 2026 increased by 3.3% compared to the same period in 2025. Total chicken meat production in Türkiye rose from 451,483 tons in the relevant period of 2025 to 466,587 tons in the same period of 2026.

## 10) Developments in Sales

From a domestic market perspective, comparing the first quarter of 2026 with the first quarter of 2025, net sales revenue from Finished Poultry Meat and Processed Products (Ready-to-Eat Products & Delicatessen) increased by 4.9% in the first quarter of 2026 compared to the same period of the previous year. The breakdown of Net Sales by type of production is presented below:

Product	(%)
Total Processed Chicken	(3.6)
Total Further Processed Products (Ready-to-Eat & Delicatessen)	25.9
<b>2024/2025 Net Sales Revenue Change</b>	<b>4.9</b>



From a domestic market perspective, comparing the first quarter of 2026 with the fourth quarter of 2025, net sales revenue from Finished Poultry Meat and Processed Products (Ready-to-Eat Products & Delicatessen) increased by 5.0% compared to the fourth quarter of 2025. The breakdown of Net Sales by type of production is presented below:

Product	(%)
Total Processed Chicken	2.8
Total Further Processed Products (Ready-to-Eat & Delicatessen)	9.6
<b>2024/2025 Net Sales Revenue Change</b>	<b>5.0</b>

From an international markets perspective, comparing the first quarter of 2026 with the first quarter of 2025, net sales revenue from Finished Poultry Meat and Processed Products (Ready-to-Eat Products & Delicatessen) increased by 20.3% in the first quarter of 2026 compared to the same period of the previous year. The breakdown of Net Sales by type of production is presented below:

Product	(%)
Total Processed Chicken	53.9
Total Further Processed Products (Ready-to-Eat & Delicatessen)	(17.4)
<b>2024/2025 Net Sales Revenue Change</b>	<b>20.3</b>

From an international markets perspective, comparing the first quarter of 2026 with the fourth quarter of 2025, net sales revenue from Finished Poultry Meat and Processed Products (Ready-to-Eat Products & Delicatessen) decreased by 15.7% compared to the fourth quarter of 2025. The breakdown of Net Sales by type of production is presented below:

Product	(%)
Total Processed Chicken	(1,6)
Total Further Processed Products (Ready-to-Eat & Delicatessen)	(35,0)
<b>2024/2025 Net Sales Revenue Change</b>	<b>(15,7)</b>

All of the above assessments have been made based on nominal values.

## F. Risk Management

### 1) Corporate Risk Management

In order to systematically and comprehensively identify, assess, control, and monitor the risks and opportunities that may affect the Company's assets, reputation, and profitability, as well as to define responsible parties and develop action plans to mitigate their potential impacts, the Risk and Internal Control Department has established a risk map and risk management policies.

These policies provide guidance on ensuring that risks are managed at the highest possible standards within the Company. They cover principles related to support and positioning, risk identification, prioritization, improvement, reporting, monitoring/supervision, and communication regarding risk management.

In line with applicable regulations and internal directives, the Company continuously monitors and manages its risks to ensure that critical risks remain within the defined tolerance levels. Furthermore, the Company develops and implements appropriate risk mitigation strategies to safeguard its operations and maintain sustainable business performance..

## 2) Early Risk Detection Committee

The purpose of the Committee is to ensure, within the framework of applicable regulations and legal requirements, the early detection of risks that may endanger the existence, development, and continuity of the Company, the implementation of necessary measures related to the identified risks, and the effective management of such risks.

The Committee meetings are held once every two months to enable the Committee to perform its duties effectively. Following each meeting, a written report on the Committee's activities, together with a summary of the meeting minutes, is submitted to the Board of Directors.

## G. Other Matters

### 1) Organizational Structure- Branches as of March 31, 2026

- İzmir Pınarbaşı Satış Şubesi
- İzmir Sarnıç Satış Şubesi
- İstanbul Hadımköy Satış Şubesi
- İstanbul Kadıköy Satış Şubesi
- İstanbul Kartal Satış Şubesi
- Muğla Satış Şubesi
- Fethiye Satış Şubesi
- Bodrum Satış Şubesi
- Trakya Satış Şubesi
- Ankara Esenboğa Satış Şubesi
- Ankara Satış Şubesi
- Samsun Satış Şubesi
- Kayseri Satış Şubesi
- Kuşadası Satış Şubesi
- Bursa Satış Şubesi
- Kemerburgaz Satış Şubesi
- Adana Satış Şubesi
- Antalya Satış Şubesi
- İzmir Armutlu Kesimhane Şubesi
- Elazığ Kesimhane Şubesi
- Elazığ Yem Fabrikası Şubesi
- Elazığ Kuluçkahane Şubesi
- Pamukçu Kuluçkahane Şubesi
- Bandırma Kuluçkahane Şubesi
- Doğruca Yem Fabrikası Şubesi
- Konya Satış Şubesi

### 2) Sustainability Principles

Environmental, social, and corporate governance activities that fall within the scope of the Sustainability Principles Compliance Framework are carried out by our Company. The implementation of sustainability principles is based on a voluntary approach, and the impacts of these principles on environmental and social risk management are evaluated by our Company. A summary of sustainability activities is provided in the Appendix.

In accordance with the Turkish Sustainability Reporting Standards ("TSRS"), companies whose shares are traded on Borsa İstanbul are required to prepare sustainability reports for financial periods beginning on or after 1 January 2024. Accordingly, all sustainability activities carried out during the year 2024 are required to be reported within the year 2025. Likewise, sustainability activities conducted during the year 2025 must be reported within the year 2026.

### 3) Significant Developments

- As disclosed on the Public Disclosure Platform on 20 January 2026, the merger transaction between TBQ, as the transferring company, and BRF, which owns all of the shares representing the capital of TBQ, as the acquiring company, was completed as of 20 January 2026 pursuant to Austrian law. As a result of the merger, the shares representing 55.03% of our Company's issued capital previously held by TBQ were transferred to BRF by virtue of the principle of universal succession. The process of recording the share acquisition resulting from the merger in the records of Merkezi Kayıt Kuruluşu A.Ş. has been completed. Following the transactions, the ultimate shareholding ratios of BRF and QH in our Company remained unchanged; accordingly, no change occurred in the Company's ultimate controlling ownership structure.
- On 26 January 2026, Banvit Bandırma Vitaminli Yem Sanayi A.Ş. Elazığ Breeding Farm Branch was established.
- In 2024, the Turkish Competition Authority initiated an investigation to assess whether companies operating in the white meat sector, including Banvit Bandırma Vitaminli Yem Sanayi A.Ş. (the "Company"), had violated Article 4 of Law No. 4054 on the Protection of Competition. On 18 September 2025, the Competition Board ruled that Article 4 of Law No. 4054 had been violated and imposed an administrative monetary fine on the Company in the amount of TRY 947,305,871.90, corresponding to approximately 3.0041% of the Company's 2024 sales. Within this scope, it was decided that the administrative fine would be paid within 30 days from 4 February 2026, the date on which the reasoned decision numbered 25-35/837-492 dated 18 September 2025 was deemed to have been electronically notified to the Company's legal representatives, benefitting from the statutory 25% reduction. A provision amounting to TRY 710,479,404 related to the Competition Authority fine was reflected in the financial statements, and the payment of the relevant amount was made under reservation on 2 March 2026.
- An administrative lawsuit has been filed seeking the annulment of the administrative fine imposed on the Company by the Competition Board, which was paid under reservation upon benefitting from the statutory 25% reduction.
- Within the scope of the Corporate Governance Communiqué (II-17.1) of the Capital Markets Board, and pursuant to Article 4.3.7 thereof, following the Company's application to the Capital Markets Board ("CMB") for its approval, the CMB has notified the Company that it has no adverse opinion regarding Meral Kurdaş, Bilgün Gürkan, and Demet Özdemir being nominated as Independent Board Member Candidates. Accordingly, Meral Kurdaş, Bilgün Gürkan, and Demet Özdemir will be submitted to the approval of the General Assembly as independent board members at the first General Assembly meeting to be held.
- Pursuant to the resolution of the Company's Board of Directors, and in accordance with the principles determined under the Turkish Commercial Code No. 6102, the Capital Markets Law No. 6362, and the regulations of the Public Oversight, Accounting and Auditing Standards Authority, it was resolved, upon the recommendation of the Audit Committee, to appoint Eren Bağımsız Denetim A.Ş. as the independent audit firm to conduct the audit of the Company's financial statements for the 2026 accounting period, to perform other related activities within the scope of the applicable legislation, and to carry out the assurance audit of sustainability reports, and to submit this appointment for the approval of the shareholders at the first General Assembly meeting.

### 4) Significant Developments After the Reporting Period

No such matter exists.



## H. Investor Relations

### INVESTOR RELATIONS

**BANVİT BANDIRMA VİTAMİNLİ YEM SANAYİ ANONİM ŞİRKETİ** shares have been traded on Borsa İstanbul since November 27, 1992.

The Company's issued capital amounts to ₺100,023,579 consisting of 100,023,579 shares, each with a nominal value of ₺1.

Listed on Borsa İstanbul A.Ş. under the BANVT ticker, the Company had a market capitalization of ₺15,023,541,566 as of March 31, 2026.

News and financial information regarding Banvit Bandırma Vitaminli Yem Sanayi Anonim Şirketi can be accessed via the Company's official website or obtained from the Investor Relations Department.

E-mail: [banvit.ir@brf.com](mailto:banvit.ir@brf.com)

Web: [www.banvit.com](http://www.banvit.com)

2025	CLOSING PRICE 2025 (TRY)	HIGHEST PRICE 2025 (TRY)	LOWEST PRICE 2025 (TRY)
BANVT	150.20	191.80	148.70

### **Disclosure on Market Data and Forward-Looking Statements**

This report has been prepared in accordance with applicable regulations for informational purposes only and does not constitute a basis for any investment decision. Industry, market, and competitive environment data included in this report have been sourced from official or third-party sources. While the Company believes that these sources are reliable, it has not independently verified the accuracy of the information. The Company, its Management, employees, or other relevant parties cannot be held liable for any direct or indirect losses or damages arising from the use of this information. This report contains forward-looking statements, which are subject to risks, uncertainties, and other important factors that are beyond or only partially within the Company's control. These factors may cause the Company's future results, performance, or achievements to differ materially from those expressed in the forward-looking statements. The forward-looking statements in this report reflect the Company's views as of the date of preparation. The Company, its Management, employees, or other relevant parties cannot be held liable for any direct or indirect losses or damages arising from the use of these statements. As of the publication date, all information presented in this report is believed to be accurate, however, the Company accepts no responsibility for errors that may occur during the writing, printing, or publishing process.